What are the indications, dosing regimens, contraindications, and monitoring recommendations for chloroquine and hydroxychloroquine in the treatment of inflammatory or autoimmune dermatologic conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Chloroquine and Hydroxychloroquine in Dermatology

Hydroxychloroquine is the preferred antimalarial for dermatologic conditions, dosed at ≤5 mg/kg actual body weight daily (maximum 400 mg/day), with mandatory baseline and annual ophthalmologic screening after 5 years of treatment. 1, 2, 3

Primary Dermatologic Indications

FDA-Approved Indications

  • Chronic discoid lupus erythematosus: 200-400 mg daily (single dose or divided) 3
  • Systemic lupus erythematosus with cutaneous manifestations: 200-400 mg daily 3

Well-Established Off-Label Uses

Based on controlled trial evidence, hydroxychloroquine/chloroquine are effective first-line therapies for:

  • Cutaneous lupus erythematosus: 50-97% effectiveness at ≤400 mg/day 4
  • Porphyria cutanea tarda: Chloroquine 125 mg twice weekly 5, 6
  • Cutaneous sarcoidosis 5, 6
  • Dermatomyositis cutaneous manifestations 5, 6

Emerging Indications

Consider trial in refractory cases:

  • Sjögren syndrome
  • Granuloma annulare
  • Erosive lichen planus 5

Critical Dosing Algorithm

Hydroxychloroquine (Preferred Agent)

  1. Calculate maximum daily dose: ≤5.0 mg/kg actual body weight 1, 2, 3
  2. Apply obesity adjustment: Cap at 400 mg/day for severely obese patients 2
  3. Standard dosing: 200-400 mg daily, given once daily or divided 3
  4. Tablet management: Use 200 mg tablets; achieve intermediate doses by splitting tablets or omitting doses on specific days weekly 2

Critical caveat: Doses exceeding 5 mg/kg increase retinopathy risk substantially 3. The therapeutic effect is cumulative, requiring weeks to months for maximum benefit 3.

Chloroquine (Alternative)

  • Maximum dose: ≤2.3 mg/kg actual body weight daily 2
  • Standard tablet: 250 mg (overdose for anyone <108 kg if given as 1 tablet daily) 2
  • Dosing equivalence: 2.3 mg/kg chloroquine ≈ 5.0 mg/kg hydroxychloroquine 2
  • Note: Chloroquine may be more toxic than hydroxychloroquine, though recent data are limited 2

Practical recommendation: Hydroxychloroquine is preferred over chloroquine for dermatologic conditions due to better safety profile and more flexible dosing 2, 5.

Absolute Contraindications

  • Known hypersensitivity to 4-aminoquinoline compounds 3
  • Psoriasis: Avoid use; can cause severe worsening 3
  • Porphyria (except porphyria cutanea tarda with specific low-dose regimen): Risk of hepatotoxicity 3

Mandatory Ophthalmologic Monitoring

Baseline Examination (Within First Year)

Required tests 2, 3:

  • Best corrected distance visual acuity
  • Spectral-domain OCT (primary screening tool)
  • Wide-pattern fundus autofluorescence
  • Automated threshold visual field (central 10 degrees)
  • Fundus examination

Purpose: Rule out preexisting macular disease AND establish comparison baseline for future screening 2

Ongoing Surveillance

  • Annual screening with OCT and fundus autofluorescence 2
  • May defer annual screening during first 5 years if no risk factors present 2
  • Visual field and multifocal ERG: Secondary confirmatory tests when abnormalities detected 2

Pattern Recognition

  • European descent: Parafoveal pattern most common 2
  • East Asian descent: Pericentral pattern predominates 2
  • Screen for both patterns regardless of ethnicity 2

High-Risk Populations Requiring Enhanced Monitoring

Increase screening frequency and consider dose reduction for:

  • Renal disease: GFR reduced by 50% doubles retinopathy risk 2
  • Concurrent tamoxifen use: Synergistic retinal toxicity 2
  • Treatment initiation at older age (>45 years) 2
  • Duration >5 years: Risk increases substantially 2, 3
  • Preexisting macular disease: Theoretical increased vulnerability 2
  • Female sex: Higher risk than males at comparable doses 2

Additional Monitoring Requirements

Cardiac Surveillance

  • Baseline ECG: Assess for QT prolongation, conduction disorders 3
  • Avoid in: Congenital/acquired QT prolongation, bradycardia <50 bpm, heart failure, recent MI 3
  • Monitor clinically: Signs of cardiomyopathy (ventricular hypertrophy, pulmonary hypertension) 3
  • Discontinue immediately if cardiotoxicity suspected 3

Hematologic Monitoring

  • Periodic complete blood counts
  • Discontinue if myelosuppression occurs 3

Renal Function

  • Monitor creatinine and GFR regularly
  • Adjust dose if renal impairment develops 2

Administration Pearls

  • Take with food or milk to minimize gastrointestinal side effects 3
  • Do not crush or divide tablets 3
  • Combination therapy: Can be used with corticosteroids, methotrexate, azathioprine, or mycophenolate to facilitate steroid tapering 1, 5
  • Quinacrine addition: If standard therapy fails, can add quinacrine to increase effectiveness 5

Risk-Benefit Context for Dermatology

The retinopathy risk with proper dosing (≤5 mg/kg/day) remains very low even after 20 years: <5% annual incremental risk after normal screening 2. Across 852 patients in cutaneous lupus studies, only one case of retinopathy occurred (after very high cumulative dose) 4. This favorable safety profile, combined with 50-97% effectiveness for cutaneous lupus, supports hydroxychloroquine as first-line therapy for inflammatory dermatologic conditions when dosed and monitored appropriately 4.

The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, abdominal pain) 3, which typically resolve with food administration or dose adjustment. Dermatologic reactions (most commonly pruritus) occur within 3 months of initiation and are generally well-tolerated or resolve with discontinuation 7.

References

Research

Use of antimalarials in dermatology.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010

Research

Dermatologic Adverse Effects of Chloroquine: A Review.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.